静脉注射的N-乙半氨酸在呼吸系统疾病中具有异常的粘液分泌
1Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. jmqu0906@163.com.
European review for medical and pharmacological sciences
|June 15, 2023
概括
静脉注射的N-乙半氨酸 (NAC) 有效地降低了的粘度,并改善了呼吸系统患者的吐. 这项大型研究证实了IV NAC.
科学领域:
- 呼吸系统医学 呼吸系统医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 有限的证据表明静脉注射N-乙半氨酸 (NAC) 的粘液解消和排泄疗效.
- 异常的粘液分泌是各种呼吸道疾病中常见的问题.
研究的目的:
- 为了评估静脉注射N-乙半氨酸 (NAC) 与安慰剂和安布罗克索尔相比的疗效.
- 评估粘度和吐难度的改善情况.
主要方法:
- 一项大型的,多中心的,随机的,受控的,双盲研究,涉及333名住院患者.
- 患者在7天内每天两次接受静脉注射N-乙半氨酸 (NAC) 600mg,安布罗克索尔化30mg或安慰剂.
- 使用排泄粘度和排泄困难的顺序尺度来测量有效性.
主要成果:
- 静脉注射的N-乙半氨酸 (NAC) 在降低唾液粘度和吐困难方面,在统计学上显著地优于安慰剂.
- 发现静脉输入的N-乙半氨酸 (NAC) 与安布罗克索尔无差.
- 静脉注射N-乙半氨酸 (NAC) 的安全概况得到证实,耐受性良好,没有新的安全问题.
结论:
- 这是第一项大规模的研究,提供了强有力的证据,证明静脉注射N-乙半氨酸 (NAC) 在异常粘液的呼吸道疾病中的有效性.
- 这些发现支持在临床环境中使用静脉注射N-乙半氨酸 (NAC),在这种情况下,静脉注射是管理粘液相关呼吸道疾病的首选方法.
相关概念视频
Acute Respiratory Failure-V
169
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
169
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
354
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
354
Drugs Used in Upper Respiratory Disorders: Overview
297
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
297
Cystic Fibrosis: Management
199
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
199
Acute Respiratory Failure-III
234
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
234
Anticholinesterase Agents: Poisoning and Treatment
926
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
926


